Search
Breast cancer screening, imaging, and care across southeastern Ontario is getting a major boost with the appointment of Dr. Doris Jabs as the Rose of Hope Clinical Chair in Breast Health at Kingston Health Sciences Centre (KHSC).
Kingston Health Sciences Centre (KHSC) has been recognized by Ontario Health’s Trillium Gift of Life Network for its outstanding efforts to integrate organ and tissue donation into quality end-of-life care.
KHSC is strengthening its position as a national leader in robotic surgery with the addition of a second surgical robot. The system, made possible through the generosity of donors, will allow KHSC to double the its number of robotic-assisted...
Kingston Health Sciences Centre (KHSC) is seeing some positive results in its effort to recruit new nurses to southeastern Ontario, part of a strategic effort to offset a Canada-wide shortage of highly trained health-care workers.
Reengineering a patient’s own immune system to hunt down and destroy cancer cells may sound like science fiction—but it’s not. It’s called Chimeric Antigen Receptor (CAR) T-cell therapy, and it’s now available at KHSC.
KHSC has reached a major milestone in the advancement of medical imaging for southeastern Ontario, officially completing construction of the region’s first PET-CT suite.
For the 13th year in a row, KHSC and its research institute, the KGHRI, have been named one of Canada’s Top 40 research hospitals by Research Infosource. This year, KHSC has climbed into 23rd place, up two spots from the previous year.
Kingston Health Sciences Centre (KHSC) has received several significant funding boosts over the last several months, aimed at supporting growth and delivering faster care, closer to home, for patients in southeastern Ontario.
Kingston Health Sciences Centre (KHSC) is receiving national accolades as an employer, provider of advanced patient care, and as a research institution, in recently released national and international rankings.
For the first time ever, researchers are studying the home use of non-hallucinogenic/micro-dose levels of psilocybin — the active compound found in psychedelic mushrooms — to treat Generalized Anxiety Disorder (GAD).